AbbVie raises full-year guidance after Skyrizi and Rinvoq growth offsets Humira losses, while Baxter posts $900 million net loss and scraps dividend.
AbbVie’s golden cross technical signal is widening, supported by a 2.8% dividend yield and rising moving averages. The company raised full-year guidance after Q1 2026 revenue growth of 31% for Skyrizi and 23% for Rinvoq, offsetting Humira’s biosimilar declines.
Baxter International, by contrast, posted a $900 million net loss in FY2025 and eliminated its dividend. Its golden cross is razor-thin, with a declining 200-day moving average, signaling weak momentum. AbbVie’s $1.73 quarterly dividend, payable August 14, 2026, extends a 13-year streak of increases.
AbbVie’s stock trades at $244.78, yielding $6.92 annually, while Baxter’s technical signal offers little fundamental support for income-focused investors.